An observational study in Immune Thrombocytopenia (ITP), sponsored by Sohag University. Not yet recruiting. Open to participants aged 16 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-01.
Sponsored by Sohag University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Purpura, Thrombocytopenic, Idiopathic by Sohag University — 6 open to participants now, 6 under way, none of them phase 3. Purpura, Thrombocytopenic, Idiopathic · Sohag University.
Among the 11 studies in Purpura, Thrombocytopenic, Idiopathic by Sohag University, this one is one of 3 that started in 2025, is one of 6 observational ones, and was the 8th registered.
505 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 160 are open to participants now.
Browse Purpura, Thrombocytopenic, Idiopathic studies →6 of the 11 studies in Purpura, Thrombocytopenic, Idiopathic by Sohag University are open now, in 1 country. Recruiting first, the newest first:
Sohag University · Sites in Egypt
Ages 18–75
Sohag University · Sites in Egypt
Ages 1–50 · Healthy volunteers
Sohag University · Sites in Egypt
Healthy volunteers
Sohag University
Ages 18–60
Sohag University
Ages 1–18 · Healthy volunteers
By country, each count listing its studies:
Of the 104 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (47%) set no upper age limit and 43 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.
This study: 16 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 3 started in 2025.
This study's planned enrollment of 40 is below the median of 122 across 99 observational studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Median enrollment 100 across the 5 interventional studies, 45 across the 6 observational. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
Sohag University is the lead sponsor of 1,236 studies on the registry; 639 are open to participants now.
3 of the studies in Purpura, Thrombocytopenic, Idiopathic by Sohag University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07046013Sohag UniversityLevel of Serum Lactate Dehydrogenase in Immune Thrombocytopenia | 2027-06 |
| NCT07014904Sohag University"Cytotoxic T Lymphocyte-Associated Antigen-4 (CTLA-4) Gene Single-nucleotide Polymorphism in Primary Immune Thrombocytopenic Purpura in Children" | 2027-06-04 |
| NCT07900334Sohag UniversityStudy of Thyroid Dysfunction in Immune Thrombocytopenic Purpura Patients | 2027-09-25 |
Add all 3 to your calendar (.ics) → With an account.
Among the 11 studies in Purpura, Thrombocytopenic, Idiopathic by Sohag University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Assessment of relation between serum lactate dehydrogenase and immune thrombocytopenia
Immune thrombocytopenia is an autoimmune disorder defined by a significantly reduced number of platelets in blood circulation.
Lactate dehydrogenase is a group of oxidoreductase isoenzymes catalyzing the reversible reaction between pyruvate and lactate.
The LDH was found to be moderately high in patients with immune thrombocytopenia at the time of diagnosis.
Sample collected from people newly diagnosed Immune thrombocytopenia at the time of diagnosis.
Laboratory investigations: LDH_CBC_ESR_Bone marrow aspirate
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
It's elevation at the time of diagnosis
Relation between serum lactate dehydrogenase and immune thrombocytopenia
Time frame: About 2 years
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Aug 2025; primary completion for Jun 2027, 22 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Purpura, Thrombocytopenic, Idiopathic →